Related Experiment Video
Updated: Apr 3, 2026

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
AR-v7 protein expression is regulated by protein kinase and phosphatase
Yinan Li1, Ning Xie1, Martin E Gleave1
1Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
Abstract:
Failure of androgen-targeted therapy and progression of castration-resistant prostate cancer (CRPC) are often attributed to sustained expression of the androgen receptor (AR) and its major splice variant, AR-v7. Although the new generation of anti-androgens such as enzalutamide effectively inhibits AR activity, accumulating pre-clinical and clinical evidence indicates that AR-v7 remains constitutively active in driving CRPC progression. However, molecular mechanisms which control AR-v7 protein expression remain unclear. We apply multiple prostate cancer cell models to demonstrate that enzalutamide induces differential activation of protein phosphatase-1 (PP-1) and Akt kinase depending on the gene context of cancer cells. The balance between PP-1 and Akt activation governs AR phosphorylation status and activation of the Mdm2 ubiquitin ligase. Mdm2 recognizes phosphorylated serine 213 of AR-v7, and induces AR-v7 ubiquitination and protein degradation. These findings highlight the decisive roles of PP-1 and Akt for AR-v7 protein expression and activities when AR is functionally blocked.
Insights
New findings reveal how protein phosphatase-1 (PP-1) and Akt kinase control androgen receptor variant 7 (AR-v7) expression. This discovery is crucial for understanding castration-resistant prostate cancer (CRPC) progression despite anti-androgen therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Signaling
Background:
- Castration-resistant prostate cancer (CRPC) progression is linked to sustained androgen receptor (AR) and its splice variant AR-v7 expression.
- Next-generation anti-androgens like enzalutamide inhibit AR activity, but AR-v7 remains active, driving CRPC.
- The molecular mechanisms regulating AR-v7 protein expression are not fully understood.
Purpose of the Study:
- To elucidate the molecular mechanisms controlling AR-v7 protein expression in prostate cancer cells.
- To investigate the roles of protein phosphatase-1 (PP-1) and Akt kinase in AR-v7 regulation.
- To understand how these pathways influence AR-v7 activity during anti-androgen therapy.
Main Methods:
- Utilized multiple prostate cancer cell models.
- Investigated the activation of protein phosphatase-1 (PP-1) and Akt kinase.
- Assessed AR phosphorylation status and Mdm2 ubiquitin ligase activation.
- Examined AR-v7 ubiquitination and protein degradation.
Main Results:
- Enzalutamide treatment induced differential activation of PP-1 and Akt kinase based on cellular context.
- The balance between PP-1 and Akt activation determined AR phosphorylation.
- Activated Mdm2 ligase recognized phosphorylated serine 213 on AR-v7, leading to its ubiquitination and degradation.
Conclusions:
- PP-1 and Akt kinase play critical roles in regulating AR-v7 protein expression.
- The PP-1/Akt balance dictates AR-v7 stability and activity.
- Targeting PP-1 and Akt pathways could offer new therapeutic strategies for CRPC by controlling AR-v7.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...

